@ivanmartellato's phenibut joint pain claims, fact-checked

What did @ivanmartellato actually say?

Honestly? It's hard to tell. The transcript provided is largely incoherent, referencing "Prija vid," "black can be counter," and someone noting "the speaker is not here." The caption, however, is more informative: it frames phenibut, ARA-290, and TB-500 as solutions for joint pain caused by overtraining, specifically mentioning cartilage wear from repetitive movement patterns like back, chest, and shoulder training without proper mobility work.

The hashtags include utilizzoChronico (chronic use) alongside peptide names, which is a significant red flag given phenibut's well-documented dependence profile. So the claim we're fact-checking is primarily caption-derived: that these compounds, individually or together, address joint pain and support athletic performance. That's a meaningful claim that deserves a real look at the evidence.

Does the science back this up?

Partially, but the framing matters enormously. TB-500 (a synthetic fragment of Thymosin Beta-4) has genuine preclinical support for tissue repair. ARA-290 is a newer erythropoietin-derived peptide with anti-inflammatory signaling. Phenibut is a GABA-B agonist with zero established role in joint repair.

For TB-500 specifically, animal studies show promotion of actin cell migration and angiogenesis relevant to wound and tendon healing (Goldstein et al., 2012, Annals of the New York Academy of Sciences). Human clinical trial data remains sparse. ARA-290 has shown promise in neuropathic pain reduction in small human trials (Brines et al., 2014, Molecular Medicine), but joint-specific evidence is preliminary at best. Phenibut is approved in some Eastern European countries as an anxiolytic and nootropic, but has no recognized mechanism for joint or cartilage repair. The idea that it belongs in the same conversation as TB-500 for musculoskeletal recovery is not supported by any evidence I can find.

What did they get wrong (or right)?

Right: the general premise that overtraining without adequate mobility work degrades joints over time is textbook sports medicine. Repetitive loading without recovery does accelerate cartilage stress, and the idea that peptide therapy might assist recovery is a legitimate area of research interest.

Wrong: including phenibut in a joint-pain protocol is a serious mismatch between mechanism and indication. Phenibut acts on GABA-B receptors and produces sedation and anxiolysis. It does not repair cartilage. More concerning, the hashtag utilizzoChronico implies recommending ongoing use, which is precisely where phenibut becomes dangerous. Physical dependence can develop within weeks of daily use, and withdrawal has been documented as severe, including seizures (Owen et al., 2016, CNS Drug Reviews). Framing chronic phenibut use as part of a joint-pain solution is misleading and potentially harmful.

What should you actually know?

These three compounds are not interchangeable, and lumping them together under "joint pain and performance" obscures real risk differences.

• TB-500: Has a plausible mechanism for soft tissue repair. Research is ongoing. Not approved for human use by the FDA. Available as a research chemical. Meaningful human trials are still lacking.
• ARA-290: Early-phase human data for neuropathic and inflammatory pain looks interesting. Not yet approved or widely available as a therapeutic. Evidence base is thin but not absent.
• Phenibut: Should not be in this conversation. It is a scheduled or controlled substance in several countries, including the UK and Australia. The FDA has issued warnings about phenibut in dietary supplements. Chronic use for musculoskeletal complaints is not evidence-based and carries genuine addiction risk.

If you are dealing with chronic joint pain from training, the first-line evidence still points to structured physical therapy, load management, and in some cases anti-inflammatory strategies, not unregulated peptides promoted on Instagram.